Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Evommune EVO756 trial fails
Business clinical trial failure

Evommune EVO756 trial fails

Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jul 07, 2026

Sentiment
-60
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Evommune's stock price plummeted 38% on the trial failure, significantly reducing market capitalization. The investigation into insider trading may lead to further legal costs and reputational damage.

biotechnology pharmaceutical
Event Summary

Evommune, Inc. (NYSE: EVMN) announced on June 29, 2026 that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial for moderate-to-severe chronic spontaneous urticaria (CSU). The stock dropped approximately 38% in a single session, erasing millions in shareholder value. Levi & Korsinsky, LLP initiated an investigation into potential securities law violations, focusing on insider stock sales by CEO Luis C. Pena and CSO Jeegar Patel that occurred one week before the disclosure. Evommune stated it will continue developing EVO756 for atopic dermatitis and migraine indications.

Key Actions
100 Evommune disclosed trial failure
80 Luis C. Pena sold shares
80 Jeegar Patel sold shares
60 Levi & Korsinsky initiated investigation Evommune
Entities Involved
stock
Evommune
Evommune's lead drug candidate failed a pivotal trial, causing a 38% stock drop and triggering a securities investigation.
Importance 100.0 Sentiment -80.0
per
Luis C. Pena
CEO Luis C. Pena sold 7,438 shares on June 22, 2026, one week before the negative trial disclosure, under a Rule 10b5-1 plan.
Importance 50.0 Sentiment -70.0
priv
Levi & Korsinsky
Levi & Korsinsky initiated an investigation into Evommune for potential securities law violations, representing affected shareholders.
Importance 40.0 Sentiment 0.0
per
Jeegar Patel
CSO Jeegar Patel exercised options and sold shares on June 22, 2026, shortly before the trial failure was announced.
Importance 40.0 Sentiment -60.0
per
Joseph E. Levi
Joseph E. Levi is the attorney leading the investigation into Evommune's insider stock sales and trial disclosure.
Importance 20.0 Sentiment 0.0
exch
New York Stock Exchange
Evommune is listed on the NYSE under ticker EVMN; the exchange is the venue for the stock trading.
Importance 5.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.